Brazil Diagnostic and Monitoring Devices Market Size and Forecast by Offering, Technology, Clinical Application, Distribution Channel, and End User: 2019-2033

---

Industry Assessment Overview

Industry Findings: Public regulatory modernization and local genomic and sequencing investments are reshaping demand for high-throughput instruments and molecular workflows. ANVISA’s regulatory agenda and RDC updates (RDC 751 and the 2024–2025 Regulatory Agenda) have increased predictability for device classification and registration (Dec-2023 to Feb-2024), which encourages larger vendors and genomic players to accelerate local partnerships and capacity investments to serve domestic hospital networks and private lab chains.

Industry Progression: One clear, verifiable commercial milestone: MGI-Tech’s strategic partnership with Dasa to expand genomic sequencing access in Brazil (Sep-2024) directly increases local sequencing capacity and creates downstream demand for sample-prep automation, reagents and monitoring. That partnership signals broader private-lab investment into genomic workflows and provides a template for other lab groups to tie sequencing scale to diagnostic and monitoring service expansion.

Industry Player Insights: Companies involved in Brazil industry are Grupo Fleury, Dasa, Hermes Pardini, and MGI Tech etc. Competitive sourcing is accelerating: Grupo Fleury’s pro-forma revenue growth and mobile-service expansion (Q1–Q3-2024/2025) and Dasa’s genomic partnerships (Sep-2024) show local laboratory chains scaling capability. MGI’s technology tie-ups support capacity for precision diagnostics (Sep-2024), pushing procurement toward vendors that bundle sequencing, automation and reagent supply for domestic customers.